Talk:Aripiprazole: Difference between revisions

(52 intermediate revisions by 3 users not shown)

Line 9:

==Chemistry==

Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is ~~C_{~~23~~}H_{~~27~~}Cl_{~~2~~}N_{~~3~~}O_{~~2}, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.

Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C23H27Cl2N3O2, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.

==Pharmacology==

Line 74:

*[https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole (Wikipedia)]

*[https://isomerdesign.com/pihkal/explore/9511 Aripiprazole (Isomer Design)]

*[https://www.erowid.org/pharms/aripiprazole/ Aripiprazole (Erowid Vault)]

*[https://go.drugbank.com/drugs/DB01238 Aripiprazole (DrugBank)]

*[https://www.drugs.com/aripiprazole.html Aripiprazole (Drugs.com)]

==References==

The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>

[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]

@@ Line 9: / Line 9: @@
 ==Chemistry==
-Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C_{23}H_{27}Cl_{2}N_{3}O_{2}, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.
+Aripiprazole is a synthetic substance of the quinolinone class and is structurally distinct from other atypical antipsychotics. Its molecular formula is C<sub>23</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>, and it has a unique mechanism of action as a dopamine-serotonin system stabilizer.
 ==Pharmacology==
@@ Line 74: / Line 74: @@
 *[https://en.wikipedia.org/wiki/Aripiprazole Aripiprazole (Wikipedia)]
 *[https://isomerdesign.com/pihkal/explore/9511 Aripiprazole (Isomer Design)]
-*[https://www.erowid.org/pharms/aripiprazole/ Aripiprazole (Erowid Vault)]
 *[https://go.drugbank.com/drugs/DB01238 Aripiprazole (DrugBank)]
+*[https://www.drugs.com/aripiprazole.html Aripiprazole (Drugs.com)]
 ==References==
 <references />
-The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>
 [[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]]